Laser-Assisted Drug Delivery for Wound Healing
What You Need to Know Before You Apply
What is the purpose of this trial?
This is a self-controlled single-site study of healthy subjects receiving an ablative fractional CO2 (carbon dioxide) laser procedure followed by topical application of NanoDOX® Hydrogel (1% doxycycline). The study includes skin biopsies to evaluate the effects of NanoDOX® Doxycycline Monohydrate Gel on wound healing after the ablative laser procedure. Study subjects will be asked to do 2 visits of 4 hours in total over approximately 1 week. An optional third visit will take place approximately 6 weeks after Visit 1. In this study, 20 subjects are expected to enroll with a goal of 12 healthy subjects to enroll and complete the study.
Who Is on the Research Team?
Dieter Manstein, MD, PhD
Principal Investigator
Massachusetts General Hospital
Are You a Good Fit for This Trial?
This trial is for healthy adults over 18, any gender and skin type, who can protect their skin from the sun and follow study rules. They must understand English and agree to participate. People with recent laser treatments, poor healing, scar issues, extreme sensitivity to light or allergies to anesthetics or doxycycline cannot join.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive CO2 ablative fractional laser treatment and NanoDOX® Hydrogel application, followed by skin biopsies
Follow-up
Participants are monitored for wound healing and drug uptake effectiveness
What Are the Treatments Tested in This Trial?
Interventions
- CO2 Ablative Fractional Laser
- NanoDOX® Hydrogel
Find a Clinic Near You
Who Is Running the Clinical Trial?
Massachusetts General Hospital
Lead Sponsor
NanoSHIFT LLC
Industry Sponsor